INVO Bioscience

IINVO BioScience, Inc. is a fertility company. It focuses on the creation of treatment options for patients diagnosed with infertility. It offers a patented medical device that is used for infertility treatment under the name INVOcell. The company was founded by Kathleen Karloff and Claude Ranoux on January 5, 2007 and is headquartered in Sarasota, FL.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NAYA Biosciences, Inc. operates a revenue-generating fertility business. It also focuses on the development of class clinical-stage assets in oncology and autoimmune diseases. The company was founded on October 14, 2024 and is headquartered in Sarasota, FL.

SAN FRANCISCO, CA / ACCESSWIRE / February 9, 2022 / Today, the global fertility market is a multi-billion industry, yet remains severely underserved, with estimates suggesting more than 90% of couples in need of infertility treatment going without care. INVO Bioscience (NASDAQ:INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the IVC procedure it enables, believes that its INVOcell and the IVC procedure are well suited to address existing industry capacity challenges and provide an affordable and effective fertility option for patients in need.

INVO Bioscience Eyes +20 U.S. Cities To Expand Rollout Of Advanced Infertility Treatment 'INVO Centers'

SARASOTA, Fla., Feb. 3, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO) ("Company") ("INVO"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the IVC procedure it enables, provides a commercialization update.

INVO Bioscience Expands U.S. Commercialization Efforts

SARASOTA, Fla. and MADRID, Dec. 16, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo culture system (IVC), INVOcell®, today announced the Company has entered into an expanded agreement with Ovoclinic, a group of clinics specialized in assisted reproductive treatments with four locations across Spain (Madrid, Marbella, Málaga, Ceuta) and collaborating centers around Europe, to accelerate adoption of INVOcell within their markets.

INVO Bioscience Enters into Agreement with Ovoclinic in Spain to Expand INVOcell Commercialization

SARASOTA, Fla., Dec. 10, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo culture system (IVC), INVOcell®, announced today that it will be participating in the Lytham Partners Winter 2021 Investor Conference taking place from December 13-16, 2021.

INVO Bioscience to Participate in the Lytham Partners Winter 2021 Investor Conference

The stock price of Invo Bioscience Inc (NASDAQ: INVO) increased by over 8% during intraday trading today. This is why it happened.

Invo Bioscience (INVO) Stock: Why The Price Increased Today

SARASOTA, Fla., Dec. 1, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo culture system (IVC), INVOcell®, today announced the Company has received approval by Medical Devices Control Division for FDA Thailand to import and commercialize INVOcell in Thailand.

INVO Bioscience Obtains Regulatory Approval to Commercialize INVOcell In Thailand

Invo BioScience Inc. (INVO) delivered earnings and revenue surprises of -20.00% and -13.10%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Invo BioScience Inc. (INVO) Reports Q3 Loss, Lags Revenue Estimates

INVO Bioscience's (INVO) CEO Steve Shum on Q3 2021 Results - Earnings Call Transcript

SARASOTA, Fla., Nov. 15, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo culture system, today announced financial and operating results for the third quarter ended September 30, 2021, and provided a business update.

INVO Bioscience Reports Third Quarter 2021 Financial and Operating Results and Provides Business Update

SARASOTA, Fla., Nov. 9, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, will report financial results for its third quarter 2021, ended September 30, 2021, after the market close on Monday, November 15, 2021.

INVO Bioscience to Report Third Quarter 2021 Financial Results on Monday, November 15, 2021

SARASOTA, Fla., Nov. 8, 2021 /PRNewswire/ -- INVO Bioscience, Inc. ("INVO" or the "Company") (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo culture system (IVC), today announced it will regain full U.S. commercialization rights for its patented INVOcell® device due to Ferring International Center S.A.

INVO Bioscience Regains Full U.S. Commercialization Rights

Invo BioScience Inc. (INVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Invo BioScience Inc. (INVO) Report Negative Q3 Earnings? What You Should Know

SARASOTA, Fla. and BALTIMORE, Oct. 20, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO) , a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, today announced that four poster abstracts were presented discussing INVOcell at the 77th Scientific Congress & Expo of the American Society for Reproductive Medicine (ASRM) being held this week in Baltimore, Maryland.

INVO Bioscience Announces Four Individual Poster Abstracts Discussing the Benefits of INVOcell Presented at the 2021 American Society for Reproductive Medicine (ASRM) Congress & Expo

The stock price of Invo Bioscience Inc (NASDAQ: INVO) increased by over 11% yesterday. This is why it happened.

INVO Stock: Why The Price Increased

SARASOTA, Fla. and MONTERREY, Mexico, Oct. 14, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo culture system (IVC), INVOcell®, today announced November 1, 2021 as the grand opening date for the Company's INVO Center joint venture, based in Monterrey, Mexico.

INVO Bioscience Announces Grand Opening of "Positib Fertility, an INVO Center" in Monterrey, Mexico on November 1, 2021

SARASOTA, Fla., Oct. 1, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo culture system (IVC), INVOcell®, today announced that it has entered into definitive agreements with institutional and accredited investors and members of INVO Bioscience's management team to purchase 1,240,763 shares of its common stock at a purchase price of $3.26 per share, in a registered direct offering priced at-the-market under Nasdaq rules, for gross proceeds of approximately $4.0 million.

INVO Bioscience Announces $4.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

SARASOTA, Fla., Sept. 9, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo culture system (IVC), INVOcell®, an affordable and effective infertility treatment, announced today that it has completed the acquisition of a Canadian-based entity that was originally formed to offer INVOcell in Canada.

INVO Bioscience Advances INVOcell® Commercialization Efforts With Acquisition in Canada

INVO Bioscience Announces Official Opening of "Bloom Fertility, an INVO Center" in Atlanta

SARASOTA, Fla., Sept. 3, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Culture System (IVC), INVOcell®, announced today that Dr. Inger Britt Carlsson will be presenting at the Association for Fertility and Reproductive Health (AFRH) virtual conference this year on September 23 rd and 24th on the topic of INVOcell® as an efficient, patient-centric and affordable fertility solution for the continent of Africa.

Dr. Inger Britt Carlsson, Vice President of Global Medical Affairs for INVO Bioscience, to Present at the 11th Annual AFRH Virtual Conference

INVO Bioscience, Inc. (INVO) CEO Steve Shum on Q2 2021 Results - Earnings Call Transcript

Invo BioScience Inc. (INVO) delivered earnings and revenue surprises of 10.53% and -0.95%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Invo BioScience Inc. (INVO) Reports Q2 Loss, Lags Revenue Estimates

SARASOTA, Fla., Aug. 16, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo culture system, today announced financial and operating results for the second quarter ended June 30, 2021 and provides a business update.

INVO Bioscience Reports Second Quarter 2021 Financial and Operating Results and Provides Business Update

Invo BioScience Inc. (INVO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

SARASOTA, Fla., Aug. 5, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, will report financial results for its second quarter 2021, ended June 30, 2021, after the market close on Monday, August 16, 2021.

INVO Bioscience to Report Second Quarter 2021 Financial Results on Monday, August 16, 2021

SARASOTA, Fla., Aug. 2, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo culture system (IVC), INVOcell®, today announced the Company's first Joint Venture INVO Center practice in the United States, based in Birmingham, Alabama, will officially open on August 9, 2021.

News for INVO Bioscience Stock (INVO)